Hypermacas Looks To Marketing To Remain Leader In Brazil Drug Market
This article was originally published in PharmAsia News
Brazil's Hypermarcas, which was the biggest seller among the country's drug makers in March, says it plans to maintain the lead by spending more on marketing and maintaining annual growth a few points above 10%.
You may also be interested in...
In the only device-related warning letter released by the US FDA this week, Avazo Healthcare was selling two COVID-19 antigen tests without approval, clearance or authorization from the agency.
A sharp decline in the number of in-person facility inspections has forced the FDA to consider creative techniques for remotely evaluating manufacturer compliance during the COVID-19 pandemic. This and other stories topped our list of most-read Medtech Insight articles in November.
A package of health proposals intended to build up the EU’s resilience to health threats while strengthening the competitiveness of Europe’s pharmaceutical industry and ensuring access to affordable drugs takes a major step through the legislative process this week.